Do NAD+ Serums Make Skin Younger? A Longevity Claim Check

Why NAD+ suddenly entered beauty language

In skincare, “anti-ageing” is increasingly being replaced by longevity, cellular energy and resilience. NAD+ fits this new vocabulary perfectly. It is a coenzyme involved in energy metabolism, DNA repair and cellular stress responses, so it arrives with genuine scientific importance. Online, however, that complex biology is often compressed into a much simpler promise: apply an NAD+ serum and ageing skin may switch back to a younger programme. LCY’s first distinction is essential. A molecule can be important inside cells without a topical product delivering enough of it, in the right form and for long enough, to create a visible human outcome. The trend is real; the performance of each finished formula still has to be demonstrated.

The trend signal: why now?

The longevity economy has moved from supplements, sleep and metabolic health into cosmetics. Brands increasingly talk about mitochondria, cellular energy and biological ageing instead of hydration alone. NAD+ is commercially powerful because its name is familiar from laboratory science and it suggests care at a deeper level than the surface. Yet launch volume and social attention are not clinical evidence. Search interest may rise while blinded, comparative trials of finished products remain scarce. For LCY, that means a high Trend Score can coexist with a cautious Evidence Score. Popularity tells us what consumers are curious about; it does not tell us whether one expensive bottle works better than a well-formulated moisturiser, sunscreen or established active.

What exactly is being claimed?

NAD+ participates in cellular redox reactions and is connected to energy metabolism. Research into age-related changes in NAD+ biology has increased interest in compounds such as niacinamide, nicotinamide riboside and NMN. Cosmetic storytelling commonly assumes three steps: the topical ingredient reaches relevant skin layers in an active form; it changes a biological pathway to a meaningful degree; and that change produces outcomes people can see, such as fewer wrinkles, more even tone or stronger barrier function. Each step needs different evidence. A result in cultured cells does not establish skin penetration. Penetration does not establish a meaningful biomarker change. A biomarker change does not automatically mean that a person will see younger-looking skin.

What the evidence actually shows

There is controlled human research on topical nicotinamide derivatives. A randomised, vehicle-controlled study published in 2007 reported improvement signals for certain signs of ageing with a specific formulation. That is useful evidence, but it does not create a class effect for every product now labelled as an NAD serum. Molecule, concentration, vehicle, stability and measured outcome may all differ. A 2026 melasma case series studied a protocol combining NAD+ with microneedling. It involved 36 participants, had no control group and tested a combination intervention. The design cannot tell us how much change came from needling, from the topical component, from natural variation or from assessment bias. It is hypothesis-generating evidence, not proof that an ordinary at-home serum reverses pigmentation or biological age.

Where hype gets ahead of evidence

The largest leap is moving from “NAD+ matters in biology” to “this bottle reverses cellular ageing.” A cosmetic formula must protect an ingredient from light, oxygen and degradation, deliver it across the skin barrier and maintain a useful concentration. Seeing a fashionable ingredient name on the label does not prove that those engineering problems have been solved. Company studies can also use small samples, short follow-up, flattering photography and outcomes that are statistically detectable but barely noticeable. Without a suitable comparator, preregistration and independent analysis, percentages can look more decisive than the experience in the mirror. LCY treats phrases such as cellular energy and epigenetic renewal as mechanism claims until finished-product human results support the promised benefit.

Safety and regulatory context

Topical niacinamide is generally well tolerated, but NAD+, niacinamide and different NAD precursors are not interchangeable names. Irritation depends on the whole formula, including solvents, fragrance, acids and preservatives. People with rosacea, eczema or an impaired barrier should patch test and stop if burning, persistent redness or rash develops. A professional protocol that uses microneedling is not equivalent to applying a serum at home. Deliberately opening the barrier can increase infection, inflammation and pigment-change risks, particularly when products were not designed for intradermal exposure. If a cosmetic is promoted as treating disease or delivering medical rejuvenation, consumers should also question whether the language has moved beyond an ordinary cosmetic claim.

LCY interpretation and a better buying filter

It is too early either to dismiss NAD+ skincare or to declare a revolution. The underlying biology is substantial, and the nicotinamide family has some topical human evidence. What is missing is broad, independent and comparative evidence for the finished longevity serums now being sold. Ask more than whether NAD appears on the ingredient list. Which molecule is used? At what concentration? How is stability protected? Was the finished formula tested, in how many people, against what comparator, for how long, and was the improvement visible as well as statistically significant? If a brand cannot answer, scientific vocabulary should not substitute for proof. LCY rating: Trend Score 84/100; Evidence Score C—plausible and interesting, but clinically incomplete.

What we still do not know

Independent randomised studies need to compare different NAD precursors, vehicles and concentrations using common outcome measures. Does a product measurably raise NAD+ in relevant human skin layers? How long does that change last, and does it improve barrier function, pigmentation or wrinkles beyond a basic moisturiser? Does benefit plateau, and which skin types are most likely to respond or react? Until those questions are answered, claims to reverse biological age run ahead of the evidence. For now, consistent sunscreen, gentle cleansing, adequate moisturisation and established actives remain a more reliable foundation for skin longevity. NAD+ may become a useful addition, but it has not yet earned the right to replace the basics. Trend Today. Evidence Before Hype.

Sources

PubMed — Trial of a topical nicotinamide derivative for ageing signs (opens in a new tab)

PubMed — 2026 NAD+ and melasma case series (opens in a new tab)